RNA interference has tremendous potential for cancer therapy but is limited by the insufficient potency of RNAi molecules after i.v. administration. We previously found that complexation with PLL(30)-PEG(5K) greatly increases the potency of 3′-cholesterol-modified siRNA [Chol-siRNA] in primary murine syngeneic 4T1 breast tumors after i.v. administration but mRNA suppression decreases 24 h after the final dose. We hypothesized that complexation of cholesterol-modified Dicer-substrate siRNA (Chol-DsiRNA) in place of Chol-siRNA can increase the potency and duration of suppression by polyplexes of PLL(30)-PEG(5K) in solid tumors. We found that replacing Chol-siRNA with Chol-DsiRNA increased polyplex loading and nuclease protection, suppressed stably expressed luciferase to the same extent in primary murine 4T1-Luc breast tumors under the current dosage regimen, but maintained suppression~72 h after the final dose. The kinetics of suppression in 4T1-Luc over 72 h, however, were similar between DsiLuc and siLuc after electroporation and between polyplexes of CholDsiLuc and Chol-siLuc after transfection, suggesting that Chol-DsiRNA polyplexes increase the duration of mRNA suppression through differences in polyplex activities in vivo. Thus, replacing Chol-siRNA with Chol-DsiRNA may significantly increase the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) and possibly other PEGylated polycationic polymers in primary tumors and metastases after i.v. administration.
Introduction
RNA interference (RNAi) is a natural, intracellular process that selectively decreases the expression of any specific protein at the mRNA level through the cytosolic localization of gene-specific dsRNA molecules including microRNA (miRNA), small, interfering RNA (siRNA), or longer dicer-substrate siRNA (DsiRNA) (Kim and Rossi, 2007) . Thus, RNAi molecules have tremendous potential in the treatment of cancer where the suppression of individual or multiple proteins can produce a therapeutic effect and/or greatly improve the efficacy of current cancer treatments.
Many clinical applications such as cancer therapy require i.v.
administration to achieve a therapeutic effect. The potencies of miRNA, siRNA, or DsiRNA after i.v. administration, however, are extremely low or undetectable due to a relatively short plasma half-life (Morrissey et al., 2005) , minimal cellular uptake, and a limited ability to escape the endosomes/lysosomes into the cytosol (Aigner, 2008; Howard, 2009; Whitehead et al., 2009) . Modifying the sense strand of nuclease-resistant siRNA with 3′-cholesterol (Chol-of Chol- * siRNA in primary murine syngeneic 4T1 breast tumors after i.v. administration to BALB/c mice (2.5 mg Chol-siRNA/kg daily for three days) without affecting body weight over the course of the 5-day study (Ambardekar et al., 2013) . More recently, complexation with an integrin-targeted PLL(45)-b-PEG(12 K)-cRGD block copolymer followed by core cross-linking was independently reported to increase the potency of Chol-siRNA (5′-cholesterol on anti-sense strand) in primary human xenogeneic HeLa cervical tumors (ectopic -SQ) after i.v. administration to nude BALB/c mice (three injections of ∼1.7 mg CholsiRNA/kg over two days), although polyplex toxicity during the study or effect of core cross-linking and cRGD modification on the activity of these "Chol-siRNA micelles" was not determined (Oe et al., 2014) . Complexation with more hydrophobic p(DMAEMA-co-BMA)-b-PEG(5K) copolymers was also recently reported to increase the potency of palmitic acid-modified siRNA (PA-siRNA) in primary human xenogeneic MDA-MB-231 breast tumors after i.v. administration to nude mice (single injection of 1 mg PA-siRNA/kg) without increasing surrogate markers of liver (ALT/AST) or kidney (BUN) toxicity in the blood 48 h after treatment (Sarett et al., 2016) . Thus, complexation with variouslymodified PEGylated polycationic polymers has great potential to increase the potency of hydrophobically-modified RNAi molecules in solid tumors and metastases.
Although complexation with PLL(30)-b-PEG(5K) or PLL(50)-b-PEG(5K) greatly increases the potency of Chol- * siRNA in primary murine syngeneic 4T1 breast tumors after i.v. administration, we found that mRNA suppression decreases within 24 h after the final dose (Ambardekar et al., 2013) , suggesting that high frequency dosing will be required to maintain mRNA suppression. As such, we wanted to identify simple approaches to increase the duration of mRNA suppression by PLL-PEG(5K) polyplexes in solid tumors.
Polyplexes of DsiRNA and Lipofectamine® 2000 are ∼100-fold more potent and suppress mRNA for a longer duration than polyplexes of siRNA and Lipofectamine® 2000 in a human embryonic kidney cell line (HEK293) (Kim et al., 2005) . Given that the increase in the potency and duration of activity with DsiRNA may be due to differences in the activities of the respective DsiRNA and siRNA polyplexes of Lipofectamine® 2000 and not the RNAi molecules themselves, we hypothesized that Chol-DsiRNA polyplexes can increase the potency and duration of mRNA suppression in primary solid tumors over Chol-siRNA polyplexes of PLL(30)-b-PEG(5K) after i.v. administration. To test this hypothesis, we compared the extent to which complexation of PLL(30)-PEG(5K) with Chol-DsiRNA in place of Chol-siRNA affects N/P ratio (loading), polyplex diameter, protection from nuclease activity in 90% (v/v) murine serum at 37°C, and mRNA suppression in murine 4T1 breast cancer epithelial cells in vitro as well as in primary murine 4T1 breast tumors after i.v. administration.
Materials and methods

Polymer
Block copolymers of methoxy-poly(ethylene glycol)-b-poly(L-lysine hydrochloride) with 5 kDa polyethylene glycol (PEG) and poly-L-lysine groups (PLL) blocks of 30 [PLL(30)-PEG(5K); Avg. MW: 9900 Da; PDI by GPC: 1-1.2; PLL block range: 27-33 PLL], or 50 [PLL(50)-PEG(5K); Avg. MW: 13,000 Da; PDI by GPC: 1-1.2; PLL block range: 45-55 PLL] were obtained from Alamanda Polymers (Huntsville, AL).
RNAi molecules
siRNA (GE Dharmacon) were 19 bp with 3′-UU overhangs on the sense and antisense strands (Ambardekar et al., 2013) . siCtrl (5′ -UGG UUU ACA UGU CGA CUA A -3′; MW: 13,278 g/mol); Chol-siCtrl (siCtrl modified with 3′-cholesterol on the sense strand through a 6 carbon hydroxyproline linker and purified by HPLC; MW: 13,983 g/ mol); siLuc (Custom anti-luciferase siRNA generated against CpG-free Luc::Sh (InvivoGen) with the Dharmacon siDESIGN center), 5′ -AGA AGG AGA UUG UGG ACU A -3′; MW: 13,293 g/mol). Chol-siLuc (siLuc modified with 3′-cholesterol as described for Chol-siCtrl; MW: 13,998 g/mol).
DsiRNA (GE Dharmacon) were an asymmetric, 25-mer dsRNA with a 3′ 2-nucleotide overhang on the antisense strand: DsiCtrl (sense: 5′ -CGU UAA UCG CGU AUA AUA CGC GUA U -3′, antisense: 5′ -AUA CGC GUA UUA UAC GCG AUU AAC G(CA) -3′; MW: 16,545 g/mol); DsiLuc (3′ extension of siLuc), sense: 5′ -AGA AGG AGA UUG UGG ACU AUG UGG C -3′, antisense: 5′ -GCC ACA UAG UCC ACA AUC UCC UUC U(UU) -3′; MW: 16,553 g/mol); Chol-DsiCtrl (DsiCtrl modified with 3′-cholesterol on the sense strand through a 6 carbon hydroxyproline linker and purified by HPLC; MW: 17,250 g/mol); CholDsiLuc (DsiLuc modified with 3′-cholesterol as described for CholDsiCtrl; MW: 17,258 g/mol). Constructs were resuspended in manufacturer's buffer per manufacturer's instructions and stored in aliquots at −80°C.
2.3. Minimum N/P ratio for complexation of DsiRNA and Chol-DsiRNA with PLL-PEG(5K) Minimum N/P molar ratios for complexation of DsiRNA and CholDsiRNA by PLL-PEG(5K) were determined with DsiCtrl or Chol-DsiCtrl as previously described for siRNA and Chol-siRNA (Ambardekar et al., 2013) using moles PLL-PEG(5K) primary amines [PLL(30)-PEG(5K): ∼3.03 mmol 1′ amines/g polymer; PLL(50)-PEG(5K): ∼3.85 mmol 1′ amines/g polymer] to moles DsiRNA phosphates (52 mol phosphate/ mol DsiRNA or Chol-DsiRNA).
Hydrodynamic diameter of DsiRNA and Chol-DsiRNA polyplexes
Hydrodynamic diameters (Z-average) of DsiCtrl and Chol-DsiCtrl polyplexes in 0.1 M HEPES [pH 7.4] at 1 mg polymer/mL and indicated N/P ratios were determined by dynamic light scattering (DLS) using a ZetaSizer Nano ZS (Malvern Instruments, Malvern, UK) equipped with He-Ne laser (λ = 633 nm) as the incident beam as previously described (Ambardekar et al., 2013) . Average diameters and polydispersity indices (n = 3 independent measurements ± SD) of PLL(30)-PEG(5K) and PLL(50)-PEG(5K) polyplexes were compared by unpaired t-test (P < 0.05).
2.5. Protection of DsiRNA and Chol-DsiRNA from serum nuclease activity Protection of DsiRNA or Chol-DsiRNA polyplexes of PLL-PEG(5K) from nuclease activity in 90% murine serum at 37°C was compared by agarose gel electrophoresis as previously described for siRNA and CholsiRNA polyplexes (Ambardekar et al., 2013) . Percent protected DsiRNA or Chol-DsiRNA [(average density of band from serum-treated polyplexes/average density of band from the corresponding buffer-treated polyplexes) * 100] ± SD (n = 2) were compared by one-way ANOVA with Tukey's post-test.
Cell culture
A murine breast cancer epithelial cell line stably expressing firefly luciferase (4T1-Luc) was grown and maintained as previously described (Ambardekar et al., 2013) . The average flux per 4T1-Luc cell was greater than recommended for in vivo imaging (3620 vs. 500 photons/s) (Lim et al., 2009 ).
Electroporation and transfection of 4T1-Luc cells
Electroporation and polyplex transfection/cytotoxicity studies in 4T1-Luc cells were performed as described (Ambardekar et al., 2013) . Average percent relative luciferase activity was expressed as [(average radiance from treated cells/average radiance from electroporation only or untransfected cells) × 100] ± SD (n = 2 independent treatments for electroporation; n = 3 independent treatments for transfection). Differences in average relative luciferase activities between electroporation treatment groups were compared by unpaired t-test at each time point. Differences in average relative luciferase activities between transfection treatment groups were compared 24 h post-transfection by one-way ANOVA with Tukey's post-test. Percent viability and total live cell count normalized to untransfected 4T1-Luc was determined at 24 h by trypan blue exclusion (Cellometer Auto T4; Nexcelom Biosciences, Lawrence, MA). Percent live cells were calculated as [(avg. total live cells treated with siRNA polyplexes/avg. total live cells without treatment) x 100] ± SD. Differences in the average total percentage of live cells were compared by one-way ANOVA with Dunnett's posttest vs. untreated 4T1-Luc.
Suppression of luciferase expression in primary murine breast tumors of 4T1-Luc
The suppression of luciferase expression in primary murine 4T1-Luc breast tumors after i.v. administration of DsiRNA or Chol-DsiRNA polyplexes of PLL-PEG(5K) was compared by IVIS as described (Ambardekar et al., 2013 
Results
Effect of PLL block length and modification of DsiRNA with 3′-cholesterol on the minimum N/P ratio required to form neutrally charged polyplexes
Complexes of DsiRNA and polycationic polymers (DsiRNA polyplexes), like siRNA polyplexes, are based on the self-assembly of DsiRNA and polymer at different molar ratios of positively charged groups (amines-N) on the polymer to negatively charged groups (phosphates-P) on the DsiRNA (N/P ratio). An N/P ratio for polyplex formation is typically initially chosen by determining the lowest N/P ratio required to form neutrally-charged polyplexes (minimum N/P ratio). A low minimum N/P ratio that still results in an active polyplex is ideal because it requires less polymer and, consequently, increases RNAi molecule loading in the polyplex. This increases the amount of RNAi molecules delivered to target cells by individual polyplexes and decreases the potential for polymer-associated toxicity.
We previously found that increasing the PLL block length of PLL-PEG(5K) from 10 to 50 lysines and modifying the sense strand of siRNA with 3′-cholesterol decreases the minimum N/P ratio for PLL-PEG(5K) to form neutral polyplexes (Ambardekar et al., 2013) . To determine whether PLL block length and/or modifying DsiRNA with 3′-cholesterol also affects the minimum N/P ratio for DsiRNA with PLL-PEG(5K), we compared the minimum N/P ratios required to neutralize DsiRNA or Chol-DsiRNA by PLL-PEG(5K) with PLL block lengths of 30 or 50 by agarose gel electrophoresis (Table 1) . We started with a PLL block length of 30 instead of 10 because PLL(10)-PEG(5K) does not protect relatively shorter Chol-siRNA from degradation in 90% (v/v) murine serum at 37°C for at least 24 h (Ambardekar et al., 2013 ) and compared whole number N/P ratios because it was experimentally convenient and provided a reasonable estimation of the lowest N/P ratio for complexation.
In contrast to siRNA and Chol-siRNA, increasing PLL block length from 30 to 50 lysines did not affect the minimum N/P ratio required for complexation of DsiRNA or Chol-DsiRNA with PLL-PEG(5K) (N/P 1), whereas modifying DsiRNA with 3′-cholesterol decreased the minimum N/P ratio required for complexation to the same extent at each PLL block length (N/P 3 to N/P 1) ( Table 1) . Agarose gel band intensities of DsiRNA and Chol-DsiRNA in the absence of PLL-PEG(5K) were statistically similar, indicating that differences in DsiRNA and Chol-DsiRNA loading were not due to differences in respective stock solution concentrations (not shown). Furthermore, Chol-DsiRNA required a lower minimum N/P ratio than Chol-siRNA for complexation with PLL(30)-PEG(5K) (N/P 1 vs. N/P 3) or PLL(50)-PEG(5K) (N/P 1 vs. N/P 2) ( Table 1 ). Thus, with the current N/P ratios and range of PLL block lengths, (i.) modifying DsiRNA with 3′-cholesterol increases DsiRNA loading by decreasing the minimum N/P ratio required for complexation with PLL-PEG(5K), whereas increasing PLL block length has no effect in the presence or absence of 3′-cholesterol and (ii.) replacing Chol-siRNA with Chol-DsiRNA increases loading with PLL(30)-PEG(5K) and PLL(50)-PEG(5K) by decreasing the minimum N/P ratio required for complexation.
Effect of PLL block length and modification of DsiRNA with 3′-cholesterol on the hydrodynamic diameter and polydispersity of DsiRNA polyplexes of PLL-PEG(5K)
We previously found that increasing PLL block length from 30 to 50 lysines has no effect on the hydrodynamic diameter of Chol-siRNA polyplexes of PLL-PEG(5K) at minimum N/P ratios that form neutral polyplexes (Ambardekar et al., 2013) . To determine whether PLL block length and/or modifying DsiRNA with 3′-cholesterol affects the diameter and/or diameter distribution of DsiRNA polyplexes of PLL-PEG(5K), the average hydrodynamic diameters and polydispersity indices of DsiRNA and Chol-DsiRNA polyplexes of PLL(30)-PEG(5K) or PLL(50)-PEG(5K) at the minimum N/P ratios required to form neutral polyplexes (Table 1) were compared by DLS (Table 2) . Unlike CholsiRNA polyplexes (Ambardekar et al., 2013) , increasing PLL block length from 30 to 50 lysines increased the hydrodynamic diameter of Chol-DsiRNA polyplexes ∼ 34 nm [46 ± 1 (SD) vs. 80 ± 2 nm, P = 0.000012] but decreased the polydispersity index ∼2-fold [0.26 ± 0.03 (SD) vs. 0.13 ± 0.01, P < 0.001] (Table 2) , whereas the polydispersity indices of DsiRNA polyplexes were too high (> 0.6) to calculate hydrodynamic diameters (Table 2) . Furthermore, the diameters of Chol-DsiRNA polyplexes were larger than the respective diameters of Chol-siRNA polyplexes formed with PLL(30)-PEG(5K) (~11 nm; P = 0.0002) or PLL(50)-PEG(5K) (~45 nm; P < 0.0001). Thus, (i.) modifying DsiRNA with 3′-cholesterol decreases the polydispersity of PLL-PEG(5K) polyplexes (ii.) increasing PLL block length increases the hydrodynamic diameter and decreases the polydispersity of Chol-DsiRNA polyplexes of PLL-PEG(5K) and (iii.) replacing CholsiRNA with Chol-DsiRNA increases the diameters of PLL-PEG(5K) polyplexes with the current N/P ratios and range of PLL block lengths.
3.3. Effect of PLL block length and modification of DsiRNA with 3′-cholesterol on the ability of PLL-PEG(5K) to protect complexed DsiRNA from nuclease degradation in high concentrations of serum DsiRNA, like siRNA, is susceptible to nuclease degradation. Thus, it is important to determine the extent to which complexation with PLL-PEG(5K) is likely to protect complexed DsiRNA from nuclease degradation in the bloodstream after i.v. administration to allow enough time for a sufficient proportion of the DsiRNA dose to accumulate in target cells within primary tumors and metastases.
We previously found that modifying siRNA with 3′-cholesterol is required for PLL-PEG(5K) with PLL block lengths up to at least 50 lysines to protect full-length siRNA from nuclease degradation in 90% (v/ v) murine serum at 37°C (Ambardekar et al., 2013) . Furthermore, increasing PLL block length from 10 to 50 lysines and increasing the nuclease resistance of siRNA through base modifications increases the extent of Chol-siRNA protection by PLL-PEG(5K) under the same conditions (Ambardekar et al., 2013) .
To determine whether PLL block length and/or modifying DsiRNA with 3′-cholesterol also affects the ability of PLL-PEG(5K) to protect DsiRNA from nuclease degradation in high concentrations of serum, DsiRNA or Chol-DsiRNA was complexed with PLL-PEG(5K) at the minimum N/P ratios that form neutral polyplexes (Table 1) . Protection against nuclease degradation in 90% (v/v) murine serum at 37°C after 24 h was then compared by polyacrylamide gel electrophoresis (Fig. 1) . DsiRNA or Chol-DsiRNA alone were undetectable after 1 h under these conditions (not shown).
Increasing PLL block length from 30 to 50 lysines increased the protection of DsiRNA (Fig. 1 , white bars) by 16% [61 ± 2 (SD) vs. 77 ± 3%, P = 0.0402] but had no effect on the already complete protection of Chol-DsiRNA (Fig. 1 (Fig. 1 , black bars vs. white bars) and, consequently, fully protected DsiRNA at both PLL block lengths under these conditions. Thus, unlike siRNA, modifying DsiRNA with 3′-cholesterol is sufficient for PLL-PEG(5K) to fully protect DsiRNA from nuclease degradation in high concentrations of murine serum at 37°C for at least 24 h with the current N/P ratios and PLL block lengths. (Kim et al., 2005) . To first determine whether DsiRNA alone increases the potency and/or duration of mRNA suppression over siRNA in 4T1 cells, the extent that equimolar amounts of siLuc or DsiLuc (3′ extension of siLuc sequence Table 1 Effect of PLL block length and modifying the sense strand with 3′-cholesterol on DsiRNA and siRNA loading. DsiCtrl, Chol-DsiCtrl (DsiCtrl modified with 3′-cholesterol on the sense strand), siCtrl, or Chol-siCtrl was added to a solution of the indicated PLL-PEG(5K) in 0.1 M HEPES [pH 7.4] at various N/P ratios, briefly vortexed, incubated at room temperature for 30 min, then separated on a TBE agarose/SYBR Green II gel. The minimum N/P ratio required for complexation (N/P ratio) was defined as the first N/P ratio where polyplexes were completely retained in the agarose gel well. The lowest experimental N/P ratio was 1/1. All N/P ratios are representative of two independent experiments. Table 2 Effect of PLL block length on the hydrodynamic diameter and polydispersity indices of DsiRNA, Chol-DsiRNA, and Chol-siRNA polyplexes of PLL-PEG(5K). Polyplexes of PLL-PEG(5K) were prepared as described at the indicated [minimum N/P ratio required to form neutral complexes] (Table 1) . Average hydrodynamic diameters (Diam.) and polydispersity indices (PDI) ± SD (n = 3 independent measurements) of PLL (30) Polyplexes of DsiCtrl, Chol-DsiCtrl, siCtrl, or Chol-siCtrl and PLL-PEG(5K) were prepared as described (Table 1) at the indicated minimum N/P ratio required to form neutral polyplexes, then incubated in buffer or 90% (v/v) murine serum at 37°C for 24 h. Remaining full-length DsiRNA (white bars), Chol-DsiRNA (black bars), siRNA (not detected), or Chol-siRNA (grey bars) were released from the polyplexes by heparin in the presence of a broad-spectrum nuclease inhibitor. CholDsiCtrl and Chol-siCtrl were additionally separated from serum proteins with water-soluble cholesterol, then quantitated by agarose gel electrophoresis. Average percent protection ± SD (n = 2) after 24 h was determined by normalizing the signal density from the remaining single band of the indicated RNAi molecule from serum-treated polyplexes to the signal density from the single band of the indicated RNAi molecule from the respective buffer-treated polyplexes and compared by one-way ANOVA with Tukey's post-test where * P < 0.05 and ** P < 0.01. DsiRNA, siRNA, Chol-DsiRNA, siRNA, and CholsiRNA alone were undetectable under these conditions (not shown). Results are representative of at least three independent experiments. a Data taken from Ambardekar et al., 2013.
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by 6 nucleotides) suppressed luciferase activity in 4T1 cells that stably express firefly luciferase (4T1-Luc) was compared by luminescence imaging 24, 48, and 72 h after electroporation (Fig. 2) . Luciferase activity is directly proportional to the intracellular concentration of luciferase protein and, consequently, proportional to luciferase mRNA levels due to the short intracellular half-life of the firefly luciferase protein in mammalian cells (∼2-3 h) (Ignowski and Schaffer, 2004; Thompson et al., 1991) . Furthermore, in contrast to transfection reagents such as Lipofectamine® 2000, electroporation is expected to deliver similar amounts of active siRNA and DsiRNA into the cytosol. Electroporation of 4T1-Luc with siLuc or DsiLuc decreased luciferase activity below electroporated 4T1-Luc to the same extent after 24 (P = 0.4461), 48 (P = 0.5323), and 72 h (P = 0.1940) (Fig. 2) . Thus, DsiRNA does not increase the potency or duration of mRNA suppression over siRNA in murine 4T1 breast cancer epithelial cells.
Effect of PLL block length and modifying DsiRNA with 3′-cholesterol on the activity of DsiRNA polyplexes of PLL-PEG(5K) in murine 4T1 breast cancer epithelial cells
We previously found that modifying siRNA with 3′-cholesterol increases the potency of siRNA polyplexes of PLL-PEG(5K) in murine breast microvascular endothelial cells (Ambardekar et al., 2011) and murine 4T1 breast cancer epithelial cells (Ambardekar et al., 2013) and changing PLL block length between 10 and 50 affects the potency of Chol-siRNA polyplexes of PLL-PEG(5K) in murine breast microvascular endothelial cells (Ambardekar et al., 2011) and murine breast cancer epithelial cells (Ambardekar et al., 2013) . To determine whether modifying DsiRNA with 3′-cholesterol and/or PLL block length also affects the potency of DsiRNA polyplexes of PLL-PEG(5K) in murine breast cancer epithelial cells in vitro, the suppression of luciferase activity in 4T1 cells that stably express firefly luciferase (4T1-Luc) by DsiLuc or Chol-DsiLuc polyplexes of PLL(30)-PEG(5K) or PLL(50)-PEG(5K) at minimum N/P ratios (Table 1 ) was compared by luminescence imaging after 24 h (Fig. 3) .
DsiLuc (Fig. 3A , dark grey bars) and Chol-DsiLuc (Fig. 3A, black bars) polyplexes decreased luciferase activity between 49% and 64% below untreated 4T1-Luc, whereas comparable polyplexes of inactive DsiCtrl (Fig. 3B , light grey bars) or Chol-DsiCtrl (Fig. 3B, white bars) or uncomplexed DsiLuc or Chol-DsiLuc (Fig. 3B , Alone) had no effect. Furthermore, trypan blue exclusion and total number of 4T1-Luc in all treatment groups were statistically similar to untreated 4T1-Luc (∼96-100%; not shown), indicating that the inhibition of luciferase activity was due to the suppression of luciferase mRNA and not cytotoxic or cytostatic effects of the polyplexes. Modifying DsiLuc with 3′-cholesterol increased the suppression of luciferase activity ∼ 12% over DsiLuc polyplexes at each PLL block length (Fig. 3, dark grey bars vs. black bars) . In contrast, increasing PLL block length from 30 to 50 lysines did not affect the extent that DsiLuc (Fig. 3A, dark grey bars) [P = 0.6230] or Chol-DsiLuc (Fig. 3A , black bars) [P = 0.9988] suppressed luciferase activity in 4T1-Luc. Thus, modifying DsiRNA with 3′-cholesterol increases the potency of DsiRNA polyplexes of PLL-PEG(5K) in murine breast cancer epithelial cells in vitro, whereas increasing PLL block length from 30 to 50 poly-L-lysines has no effect on polyplexes of DsiRNA or Chol-DsiRNA with the current N/P ratios. Furthermore, there was no difference between the activities of Chol-DsiLuc (N/P 1) and Chol-siLuc (N/P 3) polyplexes of PLL (30) (Fig. 4) . We focused on Chol-DsiRNA polyplexes of PLL(30)-PEG(5K) and not PLL(50)-PEG(5K) because they formed neutral complexes at the same low N/P ratio (Table 1) , had smaller hydrodynamic diameters with relatively low polydispersity (Table 2) , completely protected Chol-DsiRNA in 90% (v/v) murine serum at 37°C for 24 h (Fig. 1) , and suppressed stably expressed luciferase in murine 4T1 breast cancer epithelial cells to the same extent in vitro (Fig. 3) . Furthermore, PLL(30)-PEG(5K) is potentially less toxic than PLL(50)-PEG(5K) as increasing the MW of PLL alone from 24 kDa to 124 kDa increases toxicity after i.v. administration (∼11.3 mg/kg) (Moreau et al., 2002) although endotoxin levels of the respective PLL MWs were not reported.
Chol-DsiLuc polyplexes of PLL (30) (Fig. 4A, white triangles) , CholDsiLuc alone (Fig. 4A, black triangles) , or inactive polyplexes of DsiCtrl (Fig. 4B, white circles) or Chol-DsiCtrl (Fig. 4C , white squares) had no effect on the increase in luciferase activity with increasing 4T1-Luc tumor volume over time. Furthermore, none of the treatments affected the growth of 4T1-Luc tumors (Fig. 5A ) or body weights of the mice (Fig. 5B) over the course of the study, indicating that changes in luciferase activity from 4T1 tumors were not due to changes in the rate of tumor growth or acute toxicity (Lim et al., 2009) . Thus, complexation with PLL(30)-PEG(5K) increases the potency of mRNA suppression by Fig. 2 . Kinetics of siLuc and DsiLuc activity in murine 4T1 breast cancer epithelial cells over 72 h after electroporation. A murine breast cancer epithelial cell line stably expressing firefly luciferase (4T1-Luc) was electroporated alone or with 300 nM anti-luciferase siRNA (siLuc, triangles) or DsiRNA (DsiLuc, circles) then grown at 37°C. Average percent luciferase activity ± SD (n = 2 independent electroporation treatments) was calculated as the average radiance from siLuc-or DsiLuc-treated 4T1-Luc normalized to the average radiance from 4T1-Luc (electroporated alone) on the same plate and compared at the indicated time points by two-sided unpaired t-test. Results are representative of at least two independent experiments. DsiRNA in primary murine syngeneic breast tumors after i.v. administration and modifying DsiRNA with 3′-cholesterol increases the rate, potency, and duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) with the current N/P ratio and dosage regimen. Fig. 4C ) or nucleaseresistant Chol- * siLuc (taken from (Ambardekar et al., 2013) ) and PLL (30)-PEG(5K) under the same dosage regimen (Fig. 6) . Chol-DsiLuc polyplexes (Fig. 6 , black squares, N/P 1) decreased luciferase activity in 4T1-Luc tumors at the same rate and extent (∼78% by Day 2) as Chol- * siLuc polyplexes over the course of treatment (Fig. 6 , black inverted triangles, N/P 3). Chol-DsiLuc polyplexes, however, maintained suppression of luciferase activity (∼73-78%) at least 48 h longer (∼72 h vs. ∼24 h) than Chol- * siRNA polyplexes after the final day of treatment (Day 3, P = 0.0357; Day 4, P = 0.0347) despite administering ∼ 19% fewer Chol-DsiLuc molecules due to a higher MW (17,258 g Chol-DsiLuc/mol vs 13,998 g Chol-siLuc/mol). Thus, CholDsiRNA polyplexes of PLL(30)-PEG(5K) have a similar potency to CholsiRNA polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration but maintain mRNA suppression for a much longer duration with the current N/P ratios and dosage regimen.
Discussion
This study provides evidence that complexation of PLL(30)-PEG(5K) with Chol-DsiRNA in place of Chol-siRNA increases polyplex loading, nuclease protection in high concentrations of serum, and the duration of mRNA suppression in primary murine syngeneic breast tumors after i.v. administration. We found that (i.) Chol-DsiRNA required a lower minimum N/P ratio for complexation with PLL(30)-PEG(5K) than CholsiRNA (N/P 3 vs. N/P 1) (Table 1) , (ii.) Complexation with PLL(30)-PEG(5K) fully protected Chol-DsiRNA from nuclease degradation in murine serum (90% v/v) at 37°C for at least 24 h but only ∼ 60% of Chol-siRNA under the same conditions (Fig. 1) , and (iii.) Chol-DsiLuc polyplexes of PLL(30)-PEG(5K) decreased luciferase activity in 4T1-Luc tumors at the same rate and extent as Chol- * siLuc polyplexes of PLL (30)-PEG(5K) (Ambardekar et al., 2013) over the course of treatment but maintained suppression at least 48 h longer after the final day of treatment (∼72 h vs. ∼24 h) (Fig. 6 ) despite administering ∼19% fewer Chol-DsiLuc molecules than Chol-siLuc molecules. Although no differences in the mg/kg potencies of Chol-siRNA and Chol-DsiRNA polyplexes of PLL(30)-PEG(5K) were observed (Fig. 6) , it remains possible that both polyplexes saturate primary 4T1 breast tumors under the current dosage regimen.
In contrast to our study in primary murine breast tumors, there were no differences in the potencies or duration of mRNA suppression in the livers of C57BL/6 mice after i.v. administration of PEGylated lipid nanoparticles (LPN) containing DsiRNA or siRNA against PTEN or Factor VII (Foster et al., 2012) . This may be because the physicochemical properties and subsequent activities of DsiRNA and siRNA LPN are similar in vivo, especially in the liver, whereas the physicochemical properties of Chol-DsiRNA and Chol-siRNA polyplexes are different enough to affect local distribution and activities in primary 4T1 breast tumors after i.v. administration. It's also possible that nanocarrier distribution and activity in the liver is less affected by differences in physicochemical properties than in solid tumors.
4.1. Possible reasons that Chol-DsiRNA polyplexes suppress mRNA for a longer duration than Chol-siRNA polyplexes in primary murine syngeneic breast tumors after i.v. Administration
There are several possible reasons that may singly or collectively explain why Chol-DsiRNA polyplexes of PLL(30)-PEG(5K) increase the duration of mRNA suppression in primary murine tumors over CholsiRNA polyplexes of PLL(30)-PEG(5K). The first possibility, assuming that Chol-DsiRNA and Chol-siRNA polyplexes distribute to primary murine syngeneic breast tumors at similar levels, is that DsiRNA alone or Chol-DsiRNA polyplexes suppress mRNA for a longer duration in 4T1-Luc cells within the primary tumor than siRNA alone or CholsiRNA polyplexes, respectively. This is unlikely, however, because electroporation with siLuc or DsiLuc suppressed luciferase activity to the same extent over 72 h (Fig. 2) and transfection of 4T1-Luc with Fig. 3 . Effect of increasing PLL block length and modifying DsiRNA with 3′-cholesterol on the activity of PLL-PEG(5K) polyplexes of DsiRNA in murine 4T1 breast cancer epithelial cells 24 h after treatment. Murine 4T1 breast cancer cells stably expressing luciferase (4T1-Luc) were incubated for 4 h with serum-free complete DMEM containing 200 nM of DsiRNA or Chol-DsiRNA alone (Alone) or complexed with PLL30-PEG(5K) or PLL50-PEG(5K) at the indicated N/P ratio. An equal volume of complete DMEM containing 20% FBS was then added to each well and luciferase activity was measured 20 h later by bioluminescent imaging. Average percent luciferase activity ± SD (n = 2 independent treatment wells) was calculated as the average radiance from treated 4T1-Luc normalized to the average radiance from untreated 4T1-Luc on the same plate and compared by one-way ANOVA with Tukey's post-test. Results are representative of two independent experiments. Trypan blue exclusion and number of 4T1-Luc in all treatment groups was between 96% and 100% of untreated 4T1-Luc by cell counting with trypan blue exclusion (not shown).
Chol-DsiLuc or Chol-siLuc polyplexes suppressed luciferase activity to the same extent after 24 h (Fig. 3) (Ambardekar et al., 2013) up to 72 h (not shown), indicating that the potencies and kinetics of mRNA suppression by DsiLuc and siLuc are similar in 4T1 cells either alone or after complexation of their cholesterol-modified forms with PLL(30)-PEG(5K).
The second and most likely possibility is that a higher proportion of Chol-DsiRNA polyplexes localize to primary 4T1 tumors than CholsiRNA polyplexes after i.v. administration and have higher levels of loading ( Table 1 ) that deliver more RNAi molecules per localized polyplex. A higher proportion of the Chol-DsiRNA delivered to the primary tumor may also be active considering that PLL(30)-PEG(5K) fully protects Chol-DsiRNA from nuclease degradation for 24 h in 90% (v/v) murine serum ( Fig. 1) but requires modifications that increase the nuclease resistance of siRNA before completely protecting Chol-siRNA under the same conditions (Ambardekar et al., 2013) . Furthermore, considering that 3′ nucleotide overhangs on the antisense (guide) strand of siRNA are critical for RNAi activity (Caplen et al., 2001; Elbashir et al., 2001 ), Chol-DsiRNA polyplexes might be less susceptible to exonuclease removal of 3′ overhangs than Chol-siRNA polyplexes while localizing to the primary tumor and deliver a larger proportion of Chol-DsiRNA that can be converted to correspondingly higher levels of active siRNA within the cell. Although our data show that PLL(30)-PEG(5K) completely protected Chol-DsiRNA (Fig. 1) and nuclease- International Journal of Pharmaceutics 543 (2018) 130-138 resistant Chol-siRNA after 24 h in 90% (v/v) murine serum (Ambardekar et al., 2013) , it remains possible that differences in protection of 3′ overhangs of Chol-DsiRNA vs. Chol-siRNA cannot be determined by polyacrylamide gel electrophoresis because the loss of ssRNA overhangs does not decrease fluorescent dye binding enough to affect the overall intensities of the fluorescent bands. The third possibility is that low levels of Dicer substrate activity in primary tumors such as 4T1 (Grelier et al., 2009 ) decrease the rate that localized Chol-DsiRNA is converted into active siRNA. This would potentially maintain relatively constant cytosolic levels of active siRNA in 4T1 cells within the tumor for a longer duration than Chol-siRNA because the entire dose of Chol-DsiRNA would not be immediately available for incorporation into the RNAi pathway. Although transfection of 4T1-Luc with Chol-DsiLuc or Chol-siLuc polyplexes suppressed luciferase activity to the same extent up to 72 h as discussed above, it remains possible that Dicer activity in 4T1 cells within primary tumors is much lower than in 4T1 cells in vitro.
Conclusions
In summary, our results indicate that complexation of Chol-DsiRNA in place of Chol-siRNA increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration at least 48 h longer than comparable Chol-siRNA polyplexes and suggest that this is due to differences between the activities of Chol-DsiRNA and Chol-siRNA polyplexes in vivo. Thus, replacing Chol-siRNA with Chol-DsiRNA may be a simple approach to significantly increase the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) and possibly other PEGylated polycationic polymers in primary solid tumors and metastases after i.v. administration. International Journal of Pharmaceutics 543 (2018) 130-138 
